J. Foloppe et al. SITC 2026 – Abstract available on the SITC website – Download the Abstract– Download the Poster
Category: publication key en
Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties
A. Agaoua et al. frontiers in Bioengineering and Biotechnology – Article available on the frontiers website – Download the Article
A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial
C. Ottensmeier, et al. Article available on Nature Communications website – Download the Article
Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms
A. Agaoua et al. International Oncolytic Virus Conference 2026 – Download the Abstract – Download the Poster
TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment
K. Bidet-Huang World Vaccine Congress 2026 – Download the Oral Presentation
Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial
C. Ottensmeier, et al. medRxiv Preprint available on medRxiv website – Download the Article
VacDesignR®: a Tool for Optimizing Recombinant Poxvirus Vaccine Production
B. Grellier, et al. ESMO-AI 2025 Abstract available on ESMO-AI website – Download the abstract – Download the Poster
Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC
C. Le Tourneau, et al. SITC 2025 Abstract available on JITC website – Download the abstract – Download the Poster
Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors
C. Lebbe, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster
Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)
C. Le Tourneau, et al. ASCO 2025 Abstract available on the ASCO website – Download the abstract – Download the Rapid Oral Presentation